Issue 86

Eating disorders and psychedelic healthcare

Eating disorders, such as anorexia nervosa, bulimia nervosa and binge eating, afflict approximately 20 million people in Europe. In the UK, between one and three million have an eating disorder, with adolescents most at risk.

Conventional treatments are centred around psychotherapy and medical supervision, with antipsychotic and antidepressant medication administered to accelerate recovery. However, in many cases this proves ineffective, with high rates of patient remission.

Up to 85% of those with eating disorders do not respond to medication or therapy, with psychedelic medicines potentially offering new treatment paradigms.

READ MORE

WORLD HEALTH ORGANIZATION PUBLISHES MENTAL HEALTH REPORT

In 2020, the number of individuals with anxiety or depression increased by over 25%.

Read More

KPMG EVALUATES THE POTENTIAL OF PSYCHEDELIC HEALTHCARE

If clinical trials are successful, the organisation expects the market to reach US$6.8b by 2027.

Read More

BUSINESS AND INVESTMENT

Cybin reports annual financial results.

Revitalist raises nearly US$4 million in private placement.

Filament Health doses its first patient through Special Access Program.

FDA approves Mydecine’s government-funded smoking cessation trial.

Numinus files patent for psilocybin production process.

Recreational psychedelics in Canada are a long way from legalisation.

Removing the hallucinogenic effects of psychedelic medicines.

Intellectual property due diligence in psychedelic healthcare.

Health Canada’s Special Access Program.

SCIENCE AND RESEARCH

Psychedelic research centre opens at The Ohio State University.

Psilocybin-assisted therapy for alcohol use disorder.

Atlas of psychedelic research.

REGULATION AND LEGISLATION

Two psychedelic-medicine initiatives may be on the 2022 Colorado ballot.

The legality of US ketamine clinics.

Partner with us